https://doi.org/10.4081/monaldi.2010.302

Treatment of malignant pleural mesothelioma: current status and future directions

Vol. 73 No. 2 (2010): Pulmonary series
Submitted: January 19, 2016
Accepted: January 19, 2016
Published: January 19, 2016
Abstract Views: 569
PDF: 476
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

X. Dhalluin
University of Lille II, Medical School Henri Warembourg, Lille, France.
A. Scherpereel
arnaud.scherpereel@chru-lille.fr
University of Lille II, Medical School Henri Warembourg, Lille, France.
Previously considered to be rare, malignant pleural mesothelioma (MPM) is a highly aggressive tumour that has become a very important issue over recent years due to its poor prognosis and its increasing incidence mostly linked to previous asbestos exposure. An optimal treatment for MPM is not established yet; new therapies and predictive tools are still needed in the management of this cancer. Thus the aim of this review is to provide clinicians clear and up-to-dated data on the latest therapeutic strategies for MPM patients in 2010. The guidelines recently proposed by the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS) taskforce are summarized here. The authors also briefly reviewed the future directions in MPM treatment including targeted therapies, gene or cell therapies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

How to Cite

Dhalluin, X., and A. Scherpereel. 2016. “Treatment of Malignant Pleural Mesothelioma: Current Status and Future Directions”. Monaldi Archives for Chest Disease 73 (2). https://doi.org/10.4081/monaldi.2010.302.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.